Latest News about CHRS
Recent news which mentions CHRS
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
December 02, 2022
From Benzinga
Looking Into Coherus BioSciences Return On Capital Employed
August 17, 2022
Tickers
CHRS
From Benzinga
Coherus BioSciences (CHRS) Q2 2022 Earnings Call Transcript
August 06, 2022
Tickers
CHRS
From Motley Fool
From Benzinga
This Healthcare Stock Is Trading Higher By 148%: Here Are 40 Stocks Moving Premarket
August 03, 2022
From Benzinga
From Benzinga
Stocks That Hit 52-Week Lows On Thursday
June 02, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Wednesday
June 01, 2022
From Benzinga
From Benzinga
Tickers
CHRS
From Motley Fool
From Benzinga
From Benzinga
Stocks That Hit 52-Week Lows On Wednesday
April 20, 2022
From Benzinga
7 Biotech Stocks to Buy With Key Catalysts for April
April 05, 2022
From InvestorPlace
From Benzinga
Junshi Biosciences - Coherus Toripalimab Chemo Combo Met Survival Endpoints In Lung Cancer Setting
March 15, 2022
Tickers
CHRS
From Benzinga
From Benzinga
From Benzinga
Coherus BioSciences' Q4 Sales Fall 34% On Lower Udenyca Volume, Prices
February 18, 2022
From Benzinga
Coherus BioSciences (CHRS) Q4 2021 Earnings Call Transcript
February 18, 2022
Tickers
CHRS
From Motley Fool
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
February 17, 2022
From Benzinga
Earnings Scheduled For February 17, 2022
February 17, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free